Author: jlolds

Native Angeleno, professor of Neuroscience and Public Policy at George Mason University

White Board Scientific Abstract: 2011

From one of the Institute’s breakout spaces. I can see a chicken, a fruit fly, some chromosomes and a slogan.  No doubt the work of our trainees as they tend their experiments into the wee hours. In all seriousness, though, the White Boards throughout the Institute serve an incredibly important purpose as a means of catalyzing scientific discussions, very often across the disciplinary boundaries that characterize Krasnow. Even in the world of apps, the old fashioned white board can’t be beat for this purpose.

But then, this reminds me of the wonderful Intel ad that ran for a bit during the PBS new hour:

Fear of Google

From the London Review of Books, a review by Daniel Soar, here.

Money quote:

Of course, the better it gets at what it does the more money it makes, and the more money it makes the more data it gathers and the better it gets at what it does – an example of the kind of win-win feedback loop Google specialises in – but what’s surprising is that there is no obvious end to the process. 

A room with a view

Four long stories above Massachusetts Ave NW, on embassy row,  this is the Writers Room of the Cosmos Club. It’s probably my favorite place to get work done outside of my office.  Today I’m catching up on an array of paperwork after finishing the NSF panel yesterday before a lunch with one of the EU science attaches here in the Garden dining room.

What strikes me most about DC these days is the sense of collective denial about the sheer size of the cuts (most likely of federal discretionary spending) that will either be imposed by the Congressional Super Committee, or, alternatively, sequestered automatically.

Running an Institute, with a large sponsored research budget, my strategic thinking has turned towards how to position Krasnow to both survive such cuts and even to thrive. My worry is that a lot of my colleagues in similar positions just aren’t thinking about this issue.

The larger questions are first: who will be supporting basic and translational science going forward, and second: how will that happen?

There are a second level of questions which center on Federal R&D:

–Which agency portfolio’s are likely to emerge relatively unscathed?

–Will there be a “despair” effect, whereby mid-ranked scientists throw in the towel, to the advantage of the very best?

Finally, how can we create new novel mechanisms for supporting international collaborations?